Cargando…
The clinical features and estimated incidence of MIS-C in Cape Town, South Africa
BACKGROUND: Multisystem inflammatory syndrome is a severe manifestation of SARS-CoV-2 in children. The incidence of MIS-C after infection is poorly understood. There are very few cohorts describing MIS-C in Africa despite MIS-C being more common in Black children worldwide. METHODS: A cohort of chil...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9059902/ https://www.ncbi.nlm.nih.gov/pubmed/35501710 http://dx.doi.org/10.1186/s12887-022-03308-z |
_version_ | 1784698403199909888 |
---|---|
author | Butters, Claire Abraham, Deepthi Raju Stander, Raphaella Facey-Thomas, Heidi Abrahams, Debbie Faleye, Ayodele Allie, Nazneen Soni, Khushbu Rabie, Helena Scott, Christiaan Zühlke, Liesl Webb, Kate |
author_facet | Butters, Claire Abraham, Deepthi Raju Stander, Raphaella Facey-Thomas, Heidi Abrahams, Debbie Faleye, Ayodele Allie, Nazneen Soni, Khushbu Rabie, Helena Scott, Christiaan Zühlke, Liesl Webb, Kate |
author_sort | Butters, Claire |
collection | PubMed |
description | BACKGROUND: Multisystem inflammatory syndrome is a severe manifestation of SARS-CoV-2 in children. The incidence of MIS-C after infection is poorly understood. There are very few cohorts describing MIS-C in Africa despite MIS-C being more common in Black children worldwide. METHODS: A cohort of children with MIS-C and healthy children was recruited from May 2020 until May 2021 from the two main paediatric hospitals in Cape Town, South Africa. Clinical and demographic data were collected, and serum was tested for SARS-CoV-2 antibodies. The incidence of MIS-C was calculated using an estimation of population exposure from seroprevalence in the healthy group. Summary data, non-parametric comparisons and logistic regression analyses were performed. RESULTS: Sixty eight children with MIS-C were recruited with a median age of 7 years (3.6, 9.9). Ninety seven healthy children were recruited with a 30% seroprevalence. The estimated incidence of MIS-C was 22/100 000 exposures in the city in this time. Black children were over-represented in the MIS-C group (62% vs 37%, p = 0.002). The most common clinical features in MIS-C were fever (100%), tachycardia (98.5%), rash (85.3%), conjunctivitis (77.9%), abdominal pain (60.3%) and hypotension (60.3%). The median haemoglobin, sodium, neutrophil count, white cell count, CRP, ferritin, cardiac (pro-BNP, trop-T) and coagulation markers (D-dimer and fibrinogen) were markedly deranged in MIS-C. Cardiac, pulmonary, central nervous and renal organ systems were involved in 71%, 29.4%, 27.9% and 27.9% respectively. Ninety four percent received intravenous immune globulin, 64.7% received methylprednisolone and 61.7% received both. Forty percent required ICU admission, 38.2% required inotropic support, 38.2% required oxygen therapy, 11.8% required invasive ventilation and 6% required peritoneal dialysis. Older age was an independent predictor for the requirement for ionotropic support (OR = 1.523, CI 1.074, 2.16, p = 0.018). The median hospital stay duration was 7 days with no deaths. CONCLUSION: The lack of reports from Southern Africa does not reflect a lack of cases of MIS-C. MIS-C poses a significant burden to children in the region as long as the pandemic continues. MIS-C disproportionately affects black children. The clinical manifestations and outcomes of MIS-C in this region highlight the need for improved surveillance, reporting and data to inform diagnosis and treatment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12887-022-03308-z. |
format | Online Article Text |
id | pubmed-9059902 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-90599022022-05-03 The clinical features and estimated incidence of MIS-C in Cape Town, South Africa Butters, Claire Abraham, Deepthi Raju Stander, Raphaella Facey-Thomas, Heidi Abrahams, Debbie Faleye, Ayodele Allie, Nazneen Soni, Khushbu Rabie, Helena Scott, Christiaan Zühlke, Liesl Webb, Kate BMC Pediatr Research BACKGROUND: Multisystem inflammatory syndrome is a severe manifestation of SARS-CoV-2 in children. The incidence of MIS-C after infection is poorly understood. There are very few cohorts describing MIS-C in Africa despite MIS-C being more common in Black children worldwide. METHODS: A cohort of children with MIS-C and healthy children was recruited from May 2020 until May 2021 from the two main paediatric hospitals in Cape Town, South Africa. Clinical and demographic data were collected, and serum was tested for SARS-CoV-2 antibodies. The incidence of MIS-C was calculated using an estimation of population exposure from seroprevalence in the healthy group. Summary data, non-parametric comparisons and logistic regression analyses were performed. RESULTS: Sixty eight children with MIS-C were recruited with a median age of 7 years (3.6, 9.9). Ninety seven healthy children were recruited with a 30% seroprevalence. The estimated incidence of MIS-C was 22/100 000 exposures in the city in this time. Black children were over-represented in the MIS-C group (62% vs 37%, p = 0.002). The most common clinical features in MIS-C were fever (100%), tachycardia (98.5%), rash (85.3%), conjunctivitis (77.9%), abdominal pain (60.3%) and hypotension (60.3%). The median haemoglobin, sodium, neutrophil count, white cell count, CRP, ferritin, cardiac (pro-BNP, trop-T) and coagulation markers (D-dimer and fibrinogen) were markedly deranged in MIS-C. Cardiac, pulmonary, central nervous and renal organ systems were involved in 71%, 29.4%, 27.9% and 27.9% respectively. Ninety four percent received intravenous immune globulin, 64.7% received methylprednisolone and 61.7% received both. Forty percent required ICU admission, 38.2% required inotropic support, 38.2% required oxygen therapy, 11.8% required invasive ventilation and 6% required peritoneal dialysis. Older age was an independent predictor for the requirement for ionotropic support (OR = 1.523, CI 1.074, 2.16, p = 0.018). The median hospital stay duration was 7 days with no deaths. CONCLUSION: The lack of reports from Southern Africa does not reflect a lack of cases of MIS-C. MIS-C poses a significant burden to children in the region as long as the pandemic continues. MIS-C disproportionately affects black children. The clinical manifestations and outcomes of MIS-C in this region highlight the need for improved surveillance, reporting and data to inform diagnosis and treatment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12887-022-03308-z. BioMed Central 2022-05-02 /pmc/articles/PMC9059902/ /pubmed/35501710 http://dx.doi.org/10.1186/s12887-022-03308-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Butters, Claire Abraham, Deepthi Raju Stander, Raphaella Facey-Thomas, Heidi Abrahams, Debbie Faleye, Ayodele Allie, Nazneen Soni, Khushbu Rabie, Helena Scott, Christiaan Zühlke, Liesl Webb, Kate The clinical features and estimated incidence of MIS-C in Cape Town, South Africa |
title | The clinical features and estimated incidence of MIS-C in Cape Town, South Africa |
title_full | The clinical features and estimated incidence of MIS-C in Cape Town, South Africa |
title_fullStr | The clinical features and estimated incidence of MIS-C in Cape Town, South Africa |
title_full_unstemmed | The clinical features and estimated incidence of MIS-C in Cape Town, South Africa |
title_short | The clinical features and estimated incidence of MIS-C in Cape Town, South Africa |
title_sort | clinical features and estimated incidence of mis-c in cape town, south africa |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9059902/ https://www.ncbi.nlm.nih.gov/pubmed/35501710 http://dx.doi.org/10.1186/s12887-022-03308-z |
work_keys_str_mv | AT buttersclaire theclinicalfeaturesandestimatedincidenceofmiscincapetownsouthafrica AT abrahamdeepthiraju theclinicalfeaturesandestimatedincidenceofmiscincapetownsouthafrica AT standerraphaella theclinicalfeaturesandestimatedincidenceofmiscincapetownsouthafrica AT faceythomasheidi theclinicalfeaturesandestimatedincidenceofmiscincapetownsouthafrica AT abrahamsdebbie theclinicalfeaturesandestimatedincidenceofmiscincapetownsouthafrica AT faleyeayodele theclinicalfeaturesandestimatedincidenceofmiscincapetownsouthafrica AT allienazneen theclinicalfeaturesandestimatedincidenceofmiscincapetownsouthafrica AT sonikhushbu theclinicalfeaturesandestimatedincidenceofmiscincapetownsouthafrica AT rabiehelena theclinicalfeaturesandestimatedincidenceofmiscincapetownsouthafrica AT scottchristiaan theclinicalfeaturesandestimatedincidenceofmiscincapetownsouthafrica AT zuhlkeliesl theclinicalfeaturesandestimatedincidenceofmiscincapetownsouthafrica AT webbkate theclinicalfeaturesandestimatedincidenceofmiscincapetownsouthafrica AT buttersclaire clinicalfeaturesandestimatedincidenceofmiscincapetownsouthafrica AT abrahamdeepthiraju clinicalfeaturesandestimatedincidenceofmiscincapetownsouthafrica AT standerraphaella clinicalfeaturesandestimatedincidenceofmiscincapetownsouthafrica AT faceythomasheidi clinicalfeaturesandestimatedincidenceofmiscincapetownsouthafrica AT abrahamsdebbie clinicalfeaturesandestimatedincidenceofmiscincapetownsouthafrica AT faleyeayodele clinicalfeaturesandestimatedincidenceofmiscincapetownsouthafrica AT allienazneen clinicalfeaturesandestimatedincidenceofmiscincapetownsouthafrica AT sonikhushbu clinicalfeaturesandestimatedincidenceofmiscincapetownsouthafrica AT rabiehelena clinicalfeaturesandestimatedincidenceofmiscincapetownsouthafrica AT scottchristiaan clinicalfeaturesandestimatedincidenceofmiscincapetownsouthafrica AT zuhlkeliesl clinicalfeaturesandestimatedincidenceofmiscincapetownsouthafrica AT webbkate clinicalfeaturesandestimatedincidenceofmiscincapetownsouthafrica |